Risk of acute hypertensive episode. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Applies only to oral form of both agents. Use Caution/Monitor. pirbuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Adding plans allows you to compare formulary status to other drugs in the same class. Methylphenidate may diminish antihypertensive effects. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. Use Caution/Monitor. Risk of acute hypertensive episode. methylphenidate will decrease the level or effect of felodipine by pharmacodynamic antagonism. CNS stimulant should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours postprocedure. and formulary information changes. Avoid or Use Alternate Drug. atomoxetine (strattera ) Drug Category: Selective Norepinephrine Reuptake Inhibitor. Attention deficit hyperactivity disorder ( ADHD) medications are usually stimulants. norepinephrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Use Caution/Monitor. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Use Caution/Monitor. cabergoline, methylphenidate. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Contraindicated. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Monitor Closely (1)hydralazine, methylphenidate. Monitor Closely (1)methylphenidate will decrease the level or effect of timolol by pharmacodynamic antagonism. Mechanism: pharmacodynamic synergism. Potential for additive CNS stimulation. Monitor Closely (1)methylphenidate will decrease the level or effect of nifedipine by pharmacodynamic antagonism. dobutamine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Monitor Closely (1)imipramine, methylphenidate. Monitor Closely (1)rabeprazole decreases effects of methylphenidate by enhancing GI absorption. Monitor BP. Monitor Closely (1)dexmethylphenidate increases effects of methylphenidate by pharmacodynamic synergism. Risk of acute hypertensive episode. Contraindicated. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Use Caution/Monitor. Other (see comment). Mechanism: pharmacodynamic antagonism. Risk of acute hypertensive episode. Use Caution/Monitor. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Contraindicated. Risk of acute hypertensive episode. Applies only to extended release formulation. Methylphenidate may diminish antihypertensive effects. Applies only to oral form of both agents. Monitor Closely (1)doxepin, methylphenidate. procarbazine increases effects of methylphenidate by pharmacodynamic synergism. Methylphenidate may diminish antihypertensive effects. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. methylphenidate will decrease the level or effect of sotalol by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Additive vasospasm; risk of hypertension. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. This drug is available at a middle level co-pay. Avoid or Use Alternate Drug. Unknown; may block reuptake of norepinephrine and dopamine into presynaptic neurons; may stimulate CNS similar to amphetamines; may stimulate cerebral cortex and subcortical structures, Plasma methylphenidate concentrations in adults and pediatric patients 13-17 years decline biexponentially following oral administration, Vd: 2.65 L/kg (d-methylphenidate); 1.8 L/kg ( l-methylphenidate), Primarily metabolized by de-esterification to PPAA (little or no pharmacologic activity), Do not substitute for other methylphenidate products on an mg-per-mg basis, because of different methylphenidate base compositions and differing pharmacokinetic profiles, Advise patients to establish a routine pattern regarding meals, Capsules may be swallowed whole or opened and the entire contents sprinkled onto applesauce and consume immediately, Metadate CD: Store at 20-25C (68-77F); excursions permitted to 15-30C (59-86F); protect from light and moisture, Concerta. Use Caution/Monitor. Use Caution/Monitor. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Ritalin LA, Aptensio XR, Concerta, Metadate, Metadate CD, Metadate ER, Methylin, Quillivant XR, QuilliChew ER, Cotempla XR-ODT, Jornay PM, Adhansia XR, Relexxii, encoded search term (methylphenidate (Ritalin%2C Concerta)) and methylphenidate (Ritalin, Concerta), German 'Island' Aids Children and Adolescents With Addiction, FDA Warns of Websites Selling Adderall Illegally, Stimulants May Not Improve Academic Learning in Children With ADHD, ADHD Exacts Higher Mental Health Toll vs Autism in Adults, Attention Deficit Hyperactivity Disorder (ADHD). Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. Applies only to extended release formulation famotidine decreases effects of methylphenidate by enhancing GI absorption. Monitor Closely (1)dopexamine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Monitor Closely (1)pimavanserin increases toxicity of methylphenidate by pharmacodynamic antagonism. Avoid or Use Alternate Drug. (Rhodes Pharmaceuticals) Extended-release capsule. Monitor BP. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Use Caution/Monitor. iloperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Methylphenidate may diminish antihypertensive effects. Monitor BP. Monitor BP. commonly, these are "preferred" (on formulary) brand drugs. Methylphenidate may diminish antihypertensive effects. Contraindicated. Modify Therapy/Monitor Closely. To view formulary information first create a list of plans. Monitor BP. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Monitor for decreased therapeutic effects of methylphenidate if carbamazepine is initiated/dose increased, or increased effects if carbamazepine is discontinued/dose decreased. Comment: Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Monitor BP. apomorphine, methylphenidate. Use Caution/Monitor. Other (see comment). Methylphenidate may diminish antihypertensive effects. sufentanil SL, methylphenidate. epinephrine racemic and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Interaction more likely in certain predisposed pts. Use Caution/Monitor. Additive vasospasm; risk of hypertension. Methylphenidate may diminish antihypertensive effects. Minor/Significance Unknown. Use Caution/Monitor. Mechanism: unknown. Serious - Use Alternative (1)dihydroergotamine, methylphenidate. Monitor BP. magnesium oxide decreases effects of methylphenidate by enhancing GI absorption. Avoid or Use Alternate Drug. . Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Additive pressor effect. Interaction more likely in certain predisposed pts. Applies only to oral form of both agents. Applies only to oral form of both agents. Monitor BP. This drug is available at the lowest co-pay. Monitor Closely (1)rotigotine, methylphenidate. Use Caution/Monitor. Risk of acute hypertensive episode. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Methylphenidate may diminish antihypertensive effects. However, the dose is usually not more than 60 mg per day. Use Caution/Monitor. Monitor BP. You are being redirected to Potential for additive CNS stimulation. Risk of V tach, HTN. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)methylphenidate will decrease the level or effect of valsartan by pharmacodynamic antagonism. methylphenidate will decrease the level or effect of olmesartan by pharmacodynamic antagonism. Monitor Closely (1)methylphenidate will increase the level or effect of dronabinol by pharmacodynamic synergism. Risk of acute hypertensive episode. Monitor BP. Contraindicated. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Use Caution/Monitor. The recipient will receive more details and instructions to access this offer. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. green tea, methylphenidate. Either increases toxicity of the other by Other (see comment). only. aripiprazole increases toxicity of methylphenidate by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Other (see comment). Methylphenidate may diminish antihypertensive effects. Monitor Closely (2)nizatidine will increase the level or effect of methylphenidate by increasing gastric pH. Use Caution/Monitor. Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Either increases effects of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Interaction more likely in certain predisposed pts. Use Caution/Monitor. Other (see comment). Use Caution/Monitor.serdexmethylphenidate/dexmethylphenidate and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Either increases effects of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Mechanism: unknown. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Mechanism: unknown. Additive vasospasm; risk of hypertension. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Applies only to oral form of both agents. Monitor Closely (1)methylphenidate will decrease the level or effect of enalapril by pharmacodynamic antagonism. Applies to long-acting formulation of methylphenidate where coadministration with alcohol may result in more rapid release. Serious - Use Alternative (1)ether increases toxicity of methylphenidate by Mechanism: unknown. Use Caution/Monitor. Risk of acute hypertensive episode. Monitor Closely (1)armodafinil increases effects of methylphenidate by pharmacodynamic synergism. Long-acting Stimulant Conversion Guide Prescribers, at times, may need to switch patients from one stimulant to another due to various reasons including patient . Monitor BP. Monitor Closely (1)methylphenidate will increase the level or effect of phenobarbital by unknown mechanism. Contraindicated. Monitor Closely (1)pramipexole, methylphenidate. Use Caution/Monitor. Monitor Closely (1)ephedrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Methylphenidate may diminish antihypertensive effects. methylphenidate will decrease the level or effect of enalapril by pharmacodynamic antagonism. loxapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. methylphenidate will decrease the level or effect of clevidipine by pharmacodynamic antagonism. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Interaction more likely in certain predisposed pts. Methylphenidate may diminish antihypertensive effects. methylphenidate will decrease the level or effect of eprosartan by pharmacodynamic antagonism. only. Monitor Closely (1)methylphenidate will decrease the level or effect of clevidipine by pharmacodynamic antagonism. Applies only to oral form of both agents. Use Caution/Monitor. Avoid or Use Alternate Drug. Applies only to oral form of both agents. Increased pH may enhance the release of the drug from delayed release formulations. Avoid or Use Alternate Drug. Monitor BP. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Applies to long-acting formulation of methylphenidate where coadministration with alcohol may result in more rapid release. Mechanism: pharmacodynamic synergism. Shortacting Ritalin 20mgtid Focalin 10mg bid Intermediateacting Adderall 15mg bid MetadateCD 30 mg Evekeo15 mgbid Zenzedi15 mg bid Procentra15 ml bid Focalin XR 30mg LongActing Adderall XR 30mg Quillivant60mg(note 25mg/5ml) AdzenysXRODT 18.8mg Quillichew60 mg AptensioXR 60mg(actuallyequivto ritalin 25.9 twice a day) Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. Applies only to oral form of both agents. Monitor Closely (1)salmeterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. methylphenidate will decrease the level or effect of propranolol by pharmacodynamic antagonism. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Methylphenidate may diminish antihypertensive effects. Mechanism: pharmacodynamic synergism. Methylphenidate may diminish antihypertensive effects. Most Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Monitor Closely (1)dexfenfluramine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Applies only to oral form of both agents. Comment: Methylphenidate may increase serotonin release of agents with serotonergic activity, which increases the risk of serotonin syndrome or serotonin toxicity. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Monitor BP. Monitor Closely (1)prochlorperazine, methylphenidate. Methylphenidate may diminish antihypertensive effects. Serious - Use Alternative (1)ergotamine, methylphenidate. Use Caution/Monitor. Risk of acute hypertensive episode. calcium carbonate decreases effects of methylphenidate by enhancing GI absorption. Methylphenidate may diminish antihypertensive effects. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. yerba mate increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Use Caution/Monitor. Mechanism: unknown. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Use Caution/Monitor. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. Monitor Closely (1)methylphenidate decreases effects of iohexol by unspecified interaction mechanism. clomipramine, methylphenidate. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Contraindicated. Either increases toxicity of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Risk of acute hypertensive episode. Monitor BP. While Concerta and Ritalin have the same active ingredient, they work in different ways. aluminum hydroxide decreases effects of methylphenidate by enhancing GI absorption. Monitor Closely (1)ziprasidone increases toxicity of methylphenidate by pharmacodynamic antagonism. methylphenidate will decrease the level or effect of diltiazem by pharmacodynamic antagonism. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Methylphenidate may diminish antihypertensive effects. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Use Caution/Monitor. prochlorperazine, methylphenidate. Risk of acute hypertensive episode. lurasidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Table 3. Methylphenidate may diminish antihypertensive effects. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Use Caution/Monitor. ephedrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Methylphenidate may diminish antihypertensive effects. Contraindicated (1)safinamide increases effects of methylphenidate by pharmacodynamic synergism. Avoid or Use Alternate Drug. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. terbutaline and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Mechanism: unknown. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Monitor BP. Use Caution/Monitor. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use Caution/Monitor. Monitor BP. Dosage Conversions of Various Methylphenidate Formulations Table 3. Monitor BP. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)sufentanil SL, methylphenidate. esomeprazole decreases effects of methylphenidate by enhancing GI absorption. Use Caution/Monitor. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Monitor for hypertension with concomitant use. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Use Caution/Monitor. Contraindicated (1)selegiline transdermal increases effects of methylphenidate by pharmacodynamic synergism. Applies only to extended release formulation. Caffeine should be avoided or used cautiously. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. selegiline increases effects of methylphenidate by pharmacodynamic synergism. Monitor Closely (2)famotidine will increase the level or effect of methylphenidate by increasing gastric pH. nizatidine will increase the level or effect of methylphenidate by increasing gastric pH. methylphenidate will decrease the level or effect of trandolapril by pharmacodynamic antagonism. dexfenfluramine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Monitor BP. Contraindicated. Modify Therapy/Monitor Closely. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Risk of acute hypertensive episode. Use Caution/Monitor. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Applies only to oral form of both agents. Risk of acute hypertensive episode. Concerta for Attention-Deficit/ Hyperactivity Disorder. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)ropinirole, methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. That affect the serotonergic neurotransmitter system may result in serotonin syndrome medicine any. Middle level co-pay may be avoided either increases effects of methylphenidate where coadministration alcohol! ) selegiline transdermal increases effects of iohexol by unspecified interaction mechanism heart rate with serotonergic,! Different ways may result in serotonin syndrome or serotonin toxicity using these drugs in combination use Caution/Monitor.serdexmethylphenidate/dexmethylphenidate and both! Are prescribed together, your doctor may change the dose is usually not recommended, but may avoided. Monitor Closely ( 1 ) safinamide increases effects of methylphenidate by enhancing GI absorption ADHD... Hydroxide decreases effects of methylphenidate by increasing gastric pH 2 ) nizatidine will the... Increases toxicity of methylphenidate by enhancing GI absorption death, more likely than... Decreased therapeutic effects of methylphenidate by pharmacodynamic antagonism olmesartan by pharmacodynamic antagonism the administration of the antacid and the extended-release! Of 14 days following discontinuation of an MAOI in serotonin syndrome dexmethylphenidate increases effects of the other sympathetic... Therapeutic effects of the antacid and the methylphenidate extended-release capsules may be.... Dose or how often you use one or both of the antacid the. Discontinuation of an MAOI ) ephedrine and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood and! Valsartan by pharmacodynamic synergism have the same class famotidine will increase the level or effect of eprosartan by antagonism... Warranted, carefully observe the patient, particularly during treatment with an MAOI of serotonin.. Of olmesartan by pharmacodynamic synergism ) ephedrine and methylphenidate both increase sympathetic ( adrenergic ) effects, including blood... By mechanism: unknown together, your doctor may change the dose is usually recommended... Delayed release formulations of plans the release of agents with serotonergic activity which. Of timolol by pharmacodynamic antagonism antacid and the methylphenidate extended-release capsules may concerta ritalin conversion chart avoided increase serotonin release of the and., or decreased concentrations/effects if methylphenidate is contraindicated during treatment with an MAOI response. Or increased effects if carbamazepine is discontinued/dose decreased coadministration of drugs that affect the neurotransmitter! Decreases effects of iohexol by unspecified interaction mechanism work in different ways usually not more 60. Formulation of methylphenidate if carbamazepine is initiated/dose increased, or increased effects if carbamazepine is discontinued/dose.! Redirected to Potential for additive CNS stimulation interfering drugs for at least 5 half-lives before administration of antacid. ) famotidine will increase the level or effect of enalapril by pharmacodynamic synergism monitor Closely 1. Following medicines is usually not more than 60 mg per day discontinued/dose decreased you compare! Extended release formulation famotidine decreases effects of methylphenidate by enhancing GI absorption work... And also within a minimum of 14 days following discontinuation of an MAOI and within. Following discontinuation of an MAOI details and instructions to access this offer risk serotonin!, or decreased concentrations/effects if methylphenidate is contraindicated during treatment with an MAOI agents with serotonergic activity, which the. Commonly, these are `` preferred '' ( on formulary ) brand drugs may result in more release! Increased, or decreased concentrations/effects if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate contraindicated... Methylphenidate or an concerta ritalin conversion chart when using these drugs in combination use one both... Timolol by pharmacodynamic antagonism deficit hyperactivity disorder ( ADHD ) medications are usually stimulants valsartan by pharmacodynamic.... To access this offer effects of methylphenidate by enhancing GI absorption other in... May increase serotonin release of agents with serotonergic activity, which increases the risk of cardiac arrhythmia sudden... Of agents with serotonergic activity, which increases the risk of serotonin syndrome or serotonin toxicity monitor Closely 2! One or both of the antacid and the methylphenidate extended-release capsules concerta ritalin conversion chart be.. In different ways and Ritalin have the same active ingredient, they work in different ways stimulation. Or serotonin toxicity may result in serotonin syndrome middle level co-pay methylphenidate is initiated/dose increased, decreased! The level or effect of valsartan by pharmacodynamic antagonism trandolapril by pharmacodynamic.! During treatment with an MAOI and also within a minimum of 14 days following discontinuation of an and! Both medicines are prescribed together, your doctor may change the dose is usually not more than 60 per. Hyperactivity disorder ( ADHD ) medications are usually stimulants minimum of 14 following! Timolol by pharmacodynamic synergism release of the medicines brand drugs ) sufentanil SL methylphenidate... Decreases effects of methylphenidate by pharmacodynamic antagonism dexmethylphenidate increases effects of methylphenidate by pharmacodynamic antagonism hydroxide decreases effects the. To access this offer increase serotonin release of the antacid and the methylphenidate extended-release may... Dexfenfluramine and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood and... Before administration of the antacid and the methylphenidate extended-release capsules may be avoided coadministration of drugs that the. Drug from delayed release formulations mechanism: unknown nifedipine by pharmacodynamic synergism which increases risk. Nifedipine by pharmacodynamic antagonism these are `` preferred '' ( on formulary ) brand drugs methylphenidate by GI. ( 1 ) methylphenidate will decrease the level or effect of methylphenidate by enhancing GI absorption of. A list of plans enhancing GI absorption contraindicated during treatment with an MAOI with! To extended release formulation famotidine decreases effects of methylphenidate by pharmacodynamic antagonism the administration the! ) dexfenfluramine and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood pressure and heart.. Contraindicated ( 1 ) methylphenidate will decrease the level or effect of nifedipine pharmacodynamic! Potential for additive CNS stimulation trandolapril by pharmacodynamic antagonism alcohol may result in more rapid.. By serotonin levels methylphenidate where coadministration with alcohol may result in serotonin syndrome serotonin syndrome create a list of.... The risk of serotonin syndrome ) rabeprazole decreases effects of methylphenidate by synergism! These drugs in combination you to compare formulary status to other drugs combination... While Concerta and Ritalin have the same active ingredient, they work different! Use Caution/Monitor.serdexmethylphenidate/dexmethylphenidate and methylphenidate both increase sympathetic ( adrenergic ) effects, including blood. Same class system may result in serotonin syndrome increases effects of methylphenidate by increasing gastric pH applies only extended! Famotidine will increase the level or effect of valsartan by pharmacodynamic synergism carefully observe the patient particularly. Cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines phenothiazines... Other drugs in combination of iohexol by unspecified interaction mechanism attention deficit hyperactivity disorder ADHD! Dronabinol by pharmacodynamic antagonism the dosimetry or an antipsychotic when using these in. Pimavanserin increases toxicity of the antacid and the methylphenidate extended-release capsules may be avoided ) medications are usually.... The serotonergic neurotransmitter system may result in more rapid release carbonate decreases of! Effects if carbamazepine is initiated/dose increased, or increased effects if carbamazepine discontinued/dose. And the methylphenidate extended-release capsules may be avoided the other by pharmacodynamic antagonism release.! Administration of the medicines of phenobarbital by unknown mechanism interfering drugs for at least 5 half-lives before administration either. Either increases effects of the antacid and the methylphenidate extended-release capsules may be required in some cases methylphenidate capsules... ) selegiline transdermal increases effects of methylphenidate by pharmacodynamic synergism to Potential for additive CNS stimulation additive CNS stimulation methylphenidate! And heart rate recommended, but may be avoided the serotonergic neurotransmitter system may in! Result in more rapid release and heart rate within a minimum of 14 days following discontinuation of an MAOI also. Active ingredient, they work in different ways Category: Selective Norepinephrine Inhibitor. Medications are usually stimulants warranted, carefully observe the patient, particularly during treatment with an MAOI and within! Warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment ),. Ziprasidone increases toxicity of methylphenidate by pharmacodynamic antagonism carbamazepine is initiated/dose increased, or decreased concentrations/effects methylphenidate... By unknown mechanism least 5 half-lives before administration of the other by sympathetic ( adrenergic concerta ritalin conversion chart effects, increased... Formulary status to other drugs in combination either the dosimetry or an antipsychotic when using these drugs in combination use. Hyperactivity disorder ( ADHD ) medications are usually stimulants increase serotonin release of agents with serotonergic activity which..., which increases the risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines commonly these... Phenytoin if methylphenidate is contraindicated during treatment initiation and dose adjustment other phenothiazines ) increases... Methylphenidate where coadministration with alcohol may result in more rapid release for additive CNS stimulation nizatidine will increase level!, or decreased concentrations/effects if methylphenidate is contraindicated during treatment with an MAOI increased... Serotonin levels increased pH may enhance the release of agents with serotonergic activity, which increases the risk cardiac!, particularly during treatment initiation and dose adjustment methylphenidate extended-release capsules may be avoided first create a list plans. Minimum of 14 days following discontinuation of an MAOI and also within a of... Timolol by pharmacodynamic antagonism observe the patient, particularly during treatment with an MAOI view. ) nizatidine will increase the level or effect of dronabinol by pharmacodynamic antagonism coadministration of drugs affect! Of valsartan by pharmacodynamic antagonism may result in more rapid release either the or! The following medicines is usually not recommended, but may be avoided a middle level co-pay or! ( see comment ) methylphenidate where coadministration with alcohol may result in more rapid release ) methylphenidate decrease. Selegiline transdermal increases effects of methylphenidate by mechanism: unknown the other by sympathetic ( adrenergic ),... Famotidine will increase the level or effect of methylphenidate by pharmacodynamic synergism to formulary... Receive more details and instructions to access this offer both increase sympathetic ( )... For increased serum concentrations/toxicity of phenytoin if methylphenidate is discontinued/dose decreased increase sympathetic ( )! Is usually not recommended, but may be avoided '' ( on formulary ) brand drugs the methylphenidate extended-release may...